Corpus overview


Overview

MeSH Disease

HGNC Genes

SARS-CoV-2 proteins

ProteinS (1)


Filter

Genes
Diseases
SARS-CoV-2 Proteins
    displaying 1 - 2 records in total 2
    records per page




    A contact tracing prospective cohort retrieving epidemiological facts on SARS-CoV-2 transmission aspects; a serological analysis 

    Authors: Reza Vazirinejad; Parvin Khalili; Abdollah Jafarzadeh; Ziba Shabani; Ahmad Jamalizadeh; Batool Rezaei; Hassan Ahmadnia; Mohammad-taghi Rezayati; Mohammad Ebrahimian; Gholamreza Mehralinasab; Azam Bagherizadeh; Shima Bazaz; Erfan Vazirinejad

    doi:10.21203/rs.3.rs-121829/v1 Date: 2020-12-04 Source: ResearchSquare

    Introduction Novel coronavirus spread seems mysterious enough for convincing us to double check the indices being used to predict its transmission. Serological analysis was applied for assessing some metric epidemiological aspects of the i nfection MESHDand its transmissibility among people who were in contact with S ARA- HGNCCoV-2 patients.   Methods In this contact tracing prospective cohort study, 453 contact cases of forty COVID 19 patients were followed for three months.  SARS-CoV-2 patients were diagnosed by real time polymerase chain reaction testing of nasopharyngeal samples. The history of infectiousness was detected by serological testing of IgG and IgM. Trained expert team completed two questionnaires and blood samples were taken by experts in laboratory. Data were analyzed using SPSS (Ver.21) and R software. Some important epidemiological characteristics of the i nfection MESHDwere calculated. Results Mean age of S ARS-CoV-2 MESHDpatients and contact cases were 53.0±18.2 and 30.8±19.3 years, respectively. Overall R0 of the i nfection MESHDwas 2.56. Household and non-household secondary attack rates (S AR) HGNC were 20% (95%CI; 12.7 – 27.3) and 11.3% (95%CI; 6.1-16.5), respectively. Transmission probability in each contact was 0.0205 and the serial interval was 6.4±4.6 (95% CI; 5.2–7.6) days. S AR HGNCamong contact cases who exposed asymptomatic primary cases (28%, 95%CI; 10-46%) was higher than that (13.8%, 95%CI;9.4-18.2) among contact cases exposing to symptomatic patients. Conclusions We concluded a herd immunity between 60 and 65% is needed in human communities. Findings demonstrated how much reduction in i nfection MESHDR0 is predicted based on both clinical and public health interventions. 

    Designed peptides as potential fusion inhibitors against SARA HGNC-CoV-2 coronavirus infection

    Authors: Ke Chen; Shihao Bai; Xin Zou; Jie Hao; Lin-tai Da; Ze-Guang Han

    doi:10.1101/2020.06.09.142315 Date: 2020-06-10 Source: bioRxiv

    Inspired by fusion-inhibitory peptides from heptad repeat 1 (HR1) and heptad repeat 2 (HR2) domains from human immuno-deficiency virus type 1 (HIV-1) envelope glycoprotein MESHD gp41 and severe acute respiratory syndrome-coronavirus MESHD ( SARS-CoV MESHD) based on viral fusogenic mechanism in the present work, we provided a similar approach to design the synthesized peptides against the entry into host cells of SARA HGNC-CoV-2 virus that causes 2019 novel coronavirus disease MESHD ( COVID-19 MESHD). These peptides derived from HR1 and HR2 of SARA HGNC-CoV-2 spike protein PROTEIN were further tested for their interaction and potential fusion possibility through circular dichroism spectrum. Here we used the peptide COVID-2019-HR1P1 (40 amino acids) as the target, which was derived from HR1 of SARA HGNC-CoV-2 spike protein PROTEIN, while the designed peptides including COVID-2019-HR2P1 (37 amino acids), COVID-2019-HR2P2 (32 amino acids) and others derived from HR2 of SARA HGNC-CoV-2 were tested for their binding to COVID-2019-HR1P1. Interestingly, results showed that both COVID-2019-HR2P1 and COVID-2019-HR2P2 can form the complex with COVID-2019-HR1P1, respectively. This implied that these designed peptides could play an important role in blocking SARA HGNC-CoV-2 entry into mammalian host cells via viral fusogenic mechanism, and thus could be used for preventing SARA-CoV-2 infection MESHD SARA-CoV-2 infection HGNC.

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from Preprints.org and is updated on a daily basis (7am CET/CEST).
The web page can also be accessed via API.

Sources


Annotations

All
None
MeSH Disease
HGNC Genes
SARS-CoV-2 Proteins


Export subcorpus as...

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.